OncologyReport of a First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 By Graviton / 04/2015 AACR Annual Meeting
OncologyMechanistic analysis of reversible FASN inhibition in preclinical tumor models identifies highly susceptible tumor types and enriches biomarker discovery for clinical applications By natalia / 11/2014 EORTC-NCI-AACR International Conference
OncologyEfficacy of FASN-selective small molecule inhibitors of preclinical tumor models By natalia / 04/2014 AACR Annual Meeting
VirologyInhibition of Fatty Acid Synthase in vitro and in vivo Reduces RSV Replication By natalia / 01/2014 Keystone Meeting – Pathogenesis of Respiratory Viruses
OncologyCharacterization of small-molecule FASN inhibitors in preclinical tumor models By natalia / 10/2013 AACR-NCI-EORTC International Conference
VirologyA Novel, Host-Directed Small Molecule Inhibitor of HCV Displays Sustained Pharmacological Inhibition of Liver Fatty Acid Synthase By Graviton / 11/2012 AASLD The Liver Meeting